Caroline Kaercher Kramer1, Vladimir Vuksan2, Haysook Choi3, Bernard Zinman4, Ravi Retnakaran5. 1. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada; Division of Endocrinology, University of Toronto, Toronto, Canada. 2. Department of Nutritional Sciences, University of Toronto, Toronto, Canada; Division of Endocrinology, Li Ka Shing Knowledge Institute and Keenan Research Centre, St. Michael's Hospital, Toronto, Canada. 3. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada. 4. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada; Division of Endocrinology, University of Toronto, Toronto, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada. 5. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada; Division of Endocrinology, University of Toronto, Toronto, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada. Electronic address: rretnakaran@mtsinai.on.ca.
Abstract
AIMS: Recent studies have suggested that novel parameters of the insulin and glucose response on the oral glucose tolerance test (OGTT) can provide metabolic insight beyond glucose tolerance, but have not evaluated their reproducibility. Thus, our aim was to evaluate the reproducibility of these parameters and, if confirmed, characterize their clinical/pathophysiologic relevance in healthy and diabetic individuals. METHODS: Thirty healthy adults each underwent 3 replicate OGTTs, enabling assessment of the reproducibility of the following 5 parameters: time to insulin peak, shape of the glucose curve, glucose nadir below baseline, 1-h post-challenge glucose, and time to glucose peak. The only reproducible parameter was then further evaluated in 63 patients with early type 2 diabetes (T2DM) before and after 4-weeks of intensive insulin therapy (IIT) designed to improve beta-cell function (measured by Insulin Secretion-Sensitivity-Index-2 (ISSI-2)). RESULTS: Of the five parameters, only time to glucose peak displayed reliable reproducibility on replicate testing (κ=0.76). Over 80% of controls had their glucose peak at 30-min post-load, whereas all but one of the diabetic patients had their peak at 60-min or later. ISSI-2 was lower in T2DM patients with peak at ≥90-min than in those with peak at ≤60-min (P=0.012). In patients in whom IIT improved beta-cell function by ≥20% from baseline, 39.1% had glucose peak on the post-therapy OGTT shift to an earlier timepoint, as compared to 15.4% with similar shift in those without such improvement(P=0.03). CONCLUSION: Time to glucose peak is a reproducible characteristic on the OGTT and associated with beta-cell function in early T2DM.
AIMS: Recent studies have suggested that novel parameters of the insulin and glucose response on the oral glucose tolerance test (OGTT) can provide metabolic insight beyond glucose tolerance, but have not evaluated their reproducibility. Thus, our aim was to evaluate the reproducibility of these parameters and, if confirmed, characterize their clinical/pathophysiologic relevance in healthy and diabetic individuals. METHODS: Thirty healthy adults each underwent 3 replicate OGTTs, enabling assessment of the reproducibility of the following 5 parameters: time to insulin peak, shape of the glucose curve, glucose nadir below baseline, 1-h post-challenge glucose, and time to glucose peak. The only reproducible parameter was then further evaluated in 63 patients with early type 2 diabetes (T2DM) before and after 4-weeks of intensive insulin therapy (IIT) designed to improve beta-cell function (measured by Insulin Secretion-Sensitivity-Index-2 (ISSI-2)). RESULTS: Of the five parameters, only time to glucose peak displayed reliable reproducibility on replicate testing (κ=0.76). Over 80% of controls had their glucose peak at 30-min post-load, whereas all but one of the diabeticpatients had their peak at 60-min or later. ISSI-2 was lower in T2DM patients with peak at ≥90-min than in those with peak at ≤60-min (P=0.012). In patients in whom IIT improved beta-cell function by ≥20% from baseline, 39.1% had glucose peak on the post-therapy OGTT shift to an earlier timepoint, as compared to 15.4% with similar shift in those without such improvement(P=0.03). CONCLUSION: Time to glucose peak is a reproducible characteristic on the OGTT and associated with beta-cell function in early T2DM.
Authors: Kannan Kasturi; Anthony U Onuzuruike; Shwetha Kunnam; Lauren B Shomaker; Jack A Yanovski; Stephanie T Chung Journal: Pediatr Diabetes Date: 2018-12-27 Impact factor: 4.866
Authors: Stephanie T Chung; Joon Ha; Anthony U Onuzuruike; Kannan Kasturi; Mirella Galvan-De La Cruz; Brianna A Bingham; Rafeal L Baker; Jean N Utumatwishima; Lilian S Mabundo; Madia Ricks; Arthur S Sherman; Anne E Sumner Journal: Clin Endocrinol (Oxf) Date: 2017-08-06 Impact factor: 3.478
Authors: Caroline K Kramer; Chang Ye; Anthony J G Hanley; Philip W Connelly; Mathew Sermer; Bernard Zinman; Ravi Retnakaran Journal: Diabetologia Date: 2015-03-12 Impact factor: 10.122
Authors: Silva Arslanian; Laure El Ghormli; Joon Young Kim; Fida Bacha; Christine Chan; Heba M Ismail; Lorraine E Levitt Katz; Lynne Levitsky; Jeanie B Tryggestad; Neil H White Journal: Diabetes Care Date: 2018-11-19 Impact factor: 19.112
Authors: Joon Young Kim; Sara F Michaliszyn; Alexis Nasr; SoJung Lee; Hala Tfayli; Tamara Hannon; Kara S Hughan; Fida Bacha; Silva Arslanian Journal: Diabetes Care Date: 2016-06-12 Impact factor: 19.112
Authors: Silva A Arslanian; Laure El Ghormli; Joon Young Kim; Ashley H Tjaden; Elena Barengolts; Sonia Caprio; Tamara S Hannon; Kieren J Mather; Kristen J Nadeau; Kristina M Utzschneider; Steven E Kahn Journal: Diabetes Care Date: 2021-01-12 Impact factor: 19.112
Authors: Onur Cil; Marc O Anderson; Robert Yen; Bryan Kelleher; Tony L Huynh; Youngho Seo; Steven P Nilsen; Jerrold R Turner; Alan S Verkman Journal: FASEB J Date: 2019-07-12 Impact factor: 5.834